Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alnylam Pharmaceuticals Inc (ALNY)  
$147.40 0.49 (0.33%) as of 4:30 Wed 5/15


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 123,030,000
Market Cap: 18.13(B)
Last Volume: 536,143 Avg Vol: 724,527
52 Week Range: $143.31 - $211.65
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  824
Guru Rank Value     : 0.5
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,264 76,855 102,504 247,093
Total Sell Value $6,835,665 $12,957,715 $17,713,340 $48,829,179
Total People Sold 6 7 8 9
Total Sell Transactions 10 12 18 35
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 475
  Page 19 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Maraganore John Chief Executive Officer   •       •      –    2014-09-18 4 AS $78.12 $4,481,823 D/D (56,834) 104,620     -
   Maraganore John Chief Executive Officer   •       •      –    2014-09-18 4 OE $7.47 $424,550 D/D 56,834 161,454     -
   Maraganore John Chief Executive Officer   •       •      –    2014-09-17 4 AS $74.74 $4,350,750 D/D (56,834) 104,620     -
   Maraganore John Chief Executive Officer   •       •      –    2014-09-17 4 OE $7.47 $424,550 D/D 56,834 161,454     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-09-16 4 AS $71.34 $765,463 D/D (10,625) 0     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-09-16 4 OE $7.10 $93,013 D/D 10,625 10,625     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-08-18 4 AS $66.83 $909,030 D/D (13,500) 3,905     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-08-18 4 OE $7.10 $118,290 D/D 13,500 17,405     -
   Sharp Philip A Director   –       •      –    2014-07-09 4 AS $0.00 $0 I/I (21,890) 191,903     -
   Sharp Philip A Director   –       •      –    2014-07-09 4 A $0.00 $0 D/D 21,890 74,996     -
   Maraganore John Chief Executive Officer   •       •      –    2014-06-26 4 AS $64.66 $3,682,926 D/D (56,834) 106,320     -
   Maraganore John Chief Executive Officer   •       •      –    2014-06-26 4 OE $7.47 $424,550 D/D 56,834 163,154     -
   Maraganore John Chief Executive Officer   •       •      –    2014-06-25 4 AS $65.86 $3,757,171 D/D (56,834) 106,320     -
   Maraganore John Chief Executive Officer   •       •      –    2014-06-25 4 OE $7.47 $424,550 D/D 56,834 163,154     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-06-17 4 AS $69.33 $741,798 D/D (10,625) 0     -
   Vaishnaw Akshay EVP, Chief Medical Officer   •       –      –    2014-06-17 4 OE $7.10 $93,013 D/D 10,625 10,625     -
   Maraganore John Chief Executive Officer   •       •      –    2014-05-23 4 GD $0.00 $0 D/D 1,700 104,620     -
   Clarke John K Director   –       •      –    2014-05-21 4 AS $52.95 $1,882,979 D/D (35,000) 0     -
   Clarke John K Director   –       •      –    2014-05-21 4 OE $7.08 $456,850 D/D 35,000 35,000     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-05-19 4 AS $57.07 $780,684 D/D (13,500) 3,905     -
   Reid Laurence SVP, Chief Business Officer   •       –      –    2014-05-19 4 OE $7.10 $118,290 D/D 13,500 17,405     -
   Maraganore John Chief Executive Officer   •       •      –    2014-05-15 4 AS $56.06 $3,188,227 D/D (56,834) 106,320     -
   Maraganore John Chief Executive Officer   •       •      –    2014-05-15 4 OE $6.78 $400,973 D/D 56,834 163,154     -
   Maraganore John Chief Executive Officer   •       •      –    2014-05-14 4 AS $57.20 $3,259,715 D/D (56,834) 106,320     -
   Maraganore John Chief Executive Officer   •       •      –    2014-05-14 4 OE $6.78 $385,335 D/D 56,834 163,154     -
  475 Records found
  Previous  10  11  12  13  14  15  16  17  18  19    
  Page 19 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us